HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.

AbstractUNLABELLED:
One approach to treatment of primary hepatocellular carcinoma (HCC) is intraarterial injection of (131)I-lipiodol. Although clinical results have been positive, the therapy can be improved by using (188)Re instead of (131)I as the radionuclide. (188)Re is a high-energy beta-emitter, has a shorter half-life than (131)I, and has only low-intensity gamma-rays in its decay. The present study compared the cytotoxic effect of the radionuclide therapy in HCC patients treated with (131)I-lipiodol and (188)Re-4-hexadecyl 2,2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol (HDD)/lipiodol. To this end, dicentric chromosomes (DCs) were scored in metaphase spreads of peripheral blood cultures. The equivalent total-body dose was deduced from the DC yields using an in vitro dose-response curve.
METHODS:
Twenty (131)I-lipiodol treatments and 11 (188)Re-HDD/lipiodol treatments were performed on, respectively, 16 and 7 patients with inoperable HCC. Patients received a mean activity of 1.89 GBq of (131)I-lipiodol or 3.56 GBq of (188)Re-HDD/lipiodol into the liver artery by catheterization. For each patient, a blood sample was taken during the week before therapy. A blood sample was also taken 7 and 14 d after administration for the patients treated with (131)I-lipiodol and 1 or 2 d after administration for the patients treated with (188)Re-HDD/lipiodol.
RESULTS:
The mean DC yield of (188)Re-HDD/lipiodol therapy (0.087 DCs per cell) was significantly lower than that of (131)I-lipiodol therapy (0.144 DCs per cell) for the administered activities. Corresponding equivalent total-body doses were 1.04 Gy for (188)Re-HDD/lipiodol and 1.46 Gy for (131)I-lipiodol. Data analysis showed that, in comparison with (131)I-lipidol, (188)Re-HDD/lipiodol yielded a smaller cytotoxic effect and a lower radiation exposure for an expected higher tumor-killing effect.
CONCLUSION:
(188)Re is a valuable alternative for (131)I in the treatment of HCC with radiolabeled lipiodol, and a dose escalation study for (188)Re-HDD/lipiodol therapy is warranted.
AuthorsKim De Ruyck, Bieke Lambert, Klaus Bacher, Filip Gemmel, Filip De Vos, Anne Vral, Leo de Ridder, Rudi A Dierckx, Hubert Thierens
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 45 Issue 4 Pg. 612-8 (Apr 2004) ISSN: 0161-5505 [Print] United States
PMID15073257 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Comparative Study, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Iodine Radioisotopes
  • Radioisotopes
  • Rhenium
  • Iodized Oil
Topics
  • Adult
  • Aged
  • Body Burden
  • Carcinoma, Hepatocellular (blood, genetics, pathology, radiotherapy)
  • Chromosome Aberrations (radiation effects)
  • Chromosomes (radiation effects)
  • Cohort Studies
  • Dose-Response Relationship, Radiation
  • Female
  • Humans
  • Iodine Radioisotopes (adverse effects, blood, therapeutic use)
  • Iodized Oil (adverse effects, pharmacokinetics, therapeutic use)
  • Liver Neoplasms (blood, genetics, metabolism, radiotherapy)
  • Lymphocytes (pathology, radiation effects)
  • Male
  • Middle Aged
  • Radiation Injuries (etiology)
  • Radioisotopes (adverse effects, blood, therapeutic use)
  • Radiometry (methods)
  • Relative Biological Effectiveness
  • Rhenium (adverse effects, blood, therapeutic use)
  • Whole-Body Counting

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: